Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
J&J used anticompetitive tactics to prevent use of cheaper Inflectra
Sandoz is following closely behind rival from Teva and Celltrion.
EU inspectors require re-inspection of Bangalore plant.
Subcutaneous version gives more convenient injection lasting minutes, rather than several hours.
MSD may have abused dominant market position, says CMA.
FDA approves Samsung Bioepis biosimilar.
Deal with Roche paves way for near-copy of breast cancer blockbuster
Body will campaign to “Keep Medicines in Reach”
